The panel discussion at this evening’s MAPS APAC Summit continued discussing “An integrated approach to evidence generation”. The key points made were:
An integrated approach holistically identifies and prioritizes evidence needs for all stakeholders for a given asset across its life cycle.
It is backed by a formal process to keep it complete and up-to-date, as well as consistent in framework and depth across all assets.
It builds an integrated cross-functional work plan to strategically and efficiently fill high priority evidence gaps.
And it increases transparency by cataloguing past and ongoing data generation across functions.
An integrated evidence planning process involves:
Convening an Integrated Evidence Planning team.
Developing strategic context
Assembling evidence catalogues
Ideating on evidence gaps
Prioritising evidence gaps across functions.
Aligning plans to fill priority evidence gaps
Gathering and integrating input from additional stakeholders
Garnering sign-off and then executing
Ensuring living document through updates.
Thanks to the panellists:
Alan McDougall, VP Medical Affairs International Markets
Greater China Astellas
Marie Hartley, Director Medical Affairs Sandoz
Brian Bradbury, VP Center for Observational Research Amgen
Jan van Overbeeke, Partner McKinsey & Company
Shuhei Fujita, Vice President Medical Science Astellas
Gemma Zhu, Senior Director Clinical and Outcomes Research Bayer
HPG (Healthcare Professionals Group)
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
#MedicalAffairs #MSL #drugdevelopment #pharmaceuticals #biotechnology